The rationale for the use of TKIs is based on the study of Pnan et al. who demonstrated an increased phosphorylation of c-MET in the immunohistochemistry of ACC tissue samples compared to adrenocortical adenomas and normal cortex, thus speculating that targeting c-MET could provide a breakthrough in the management of these aggressive diseases [69]. The gene discussed is MET; the disease is adrenal cortex adenoma.